Summary of Significant Accounting Policies - Revenue from contract with customers (Details) - GlaxoSmithKline Intellectual Property Development Ltd - Collaboration and License Agreement £ in Millions |
1 Months Ended | 12 Months Ended | 16 Months Ended | 55 Months Ended | |||
|---|---|---|---|---|---|---|---|
|
Sep. 30, 2018
USD ($)
|
Sep. 30, 2017
GBP (£)
|
Sep. 30, 2017
USD ($)
|
Jun. 30, 2014
USD ($)
|
Dec. 31, 2018
USD ($)
contract
|
Dec. 31, 2018
USD ($)
|
Dec. 31, 2018
USD ($)
|
|
| Collaboration and License Agreement | |||||||
| Number of contracts with customers | contract | 1 | ||||||
| Option Exercise Fee, received | £ 20 | $ 26,600,000 | |||||
| Upfront payment received | $ 42,123,000 | ||||||
| Option exercise fee received | $ 26,610,000 | ||||||
| Option exercise fee | $ 13,175,000 | $ 39,785,000 | |||||
| Amount of development milestone achieved | $ 66,404,000 | ||||||
| Estimate of variable consideration | $ 0 | ||||||
| X | ||||||||||
- Definition Represents cash received upon achievement of development milestones. No definition available.
|
| X | ||||||||||
- Definition Represents the variable consideration entitled upon achievement of development milestones. No definition available.
|
| X | ||||||||||
- Definition The amount of first tranche of the option exercise fee receivable for exercising of agreement. No definition available.
|
| X | ||||||||||
- Definition Represents the total number of contracts with customers. No definition available.
|
| X | ||||||||||
- Definition Option exercise fee No definition available.
|
| X | ||||||||||
- Definition Option exercise fee received. No definition available.
|
| X | ||||||||||
- Definition Upfront payment received. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|